As of June 13, 2025, Nanjing Hicin Pharmaceutical Co Ltd (300584.SZ) reports a Gross Margin of 81.55%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Nanjing Hicin Pharmaceutical Co Ltd's Gross Margin
Over recent years, Nanjing Hicin Pharmaceutical Co Ltd's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 81.55% |
| 2023-12-31 | 80.44% |
| 2022-12-31 | 74.59% |
| 2021-12-31 | 80.99% |
| 2020-12-31 | 75.28% |
This slight upward trend highlights how Nanjing Hicin Pharmaceutical Co Ltd manages its operational efficiency and pricing power over time.
Comparing Nanjing Hicin Pharmaceutical Co Ltd's Gross Margin to Peers
To better understand Nanjing Hicin Pharmaceutical Co Ltd's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Nanjing Hicin Pharmaceutical Co Ltd (300584.SZ) | 81.55% |
| Ginwa Enterprise Group Inc (600080.SS) | 78.30% |
| Hunan Hansen Pharmaceutical Co Ltd (002412.SZ) | 75.84% |
| Jilin Jian Yisheng Pharmaceutical Co Ltd (002566.SZ) | 74.23% |
| Inner Mongolia Furui Medical Science Co Ltd (300049.SZ) | 74.00% |
| Guiyang Xintian Pharmaceutical Co Ltd (002873.SZ) | 73.10% |
Compared to its competitors, Nanjing Hicin Pharmaceutical Co Ltd's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.